













AGREE APPRAISAL INSTRUMENT 

1. SCOPE AND PURPOSE (1-3)

- 2. STAKEHOLDER INVOLVEMENT (4-7)
- 3. RIGOUR OF DEVELOPMENT (8-14)
- 4. CLARITY AND PRESENTATION (15-18)
- 5. APPLICABILITY (19-21)
- 6. EDITORIAL INDEPENDENCE (22-23)

Is concerned with the overall aim of the guideline, the specific clinical questions and the target patient population

AGREE APPRAISAL INSTRUMENT 

- 1. SCOPE AND PURPOSE (1-3)
- 2. STAKEHOLDER INVOLVEMENT (4-7)**
- 3. RIGOUR OF DEVELOPMENT (8-14)
- 4. CLARITY AND PRESENTATION (15-18)
- 5. APPLICABILITY (19-21)
- 6. EDITORIAL INDEPENDENCE (22-23)

Focuses on the extent to which the guideline represents the views of its intended users

AGREE APPRAISAL INSTRUMENT 

- 1. SCOPE AND PURPOSE (1-3)
- 2. STAKEHOLDER INVOLVEMENT (4-7)
- 3. RIGOUR OF DEVELOPMENT (8-14)**
- 4. CLARITY AND PRESENTATION (15-18)
- 5. APPLICABILITY (19-21)
- 6. EDITORIAL INDEPENDENCE (22-23)

Relates to the process used to gather and synthesise the evidence, the methods to formulate the recommendations and to update them

AGREE APPRAISAL INSTRUMENT 

1. SCOPE AND PURPOSE (1-3)
2. STAKEHOLDER INVOLVEMENT (4-7)
3. RIGOUR OF DEVELOPMENT (8-14)
- 4. CLARITY AND PRESENTATION (15-18)**
5. APPLICABILITY (19-21)
6. EDITORIAL INDEPENDENCE (22-23)

Deals with the language and format of the guideline

AGREE APPRAISAL INSTRUMENT 

1. SCOPE AND PURPOSE (1-3)
2. STAKEHOLDER INVOLVEMENT (4-7)
3. RIGOUR OF DEVELOPMENT (8-14)
4. CLARITY AND PRESENTATION (15-18)
- 5. APPLICABILITY (19-21)**
6. EDITORIAL INDEPENDENCE (22-23)

Pertains to the likely organisational, behavioural and costs implications of applying the guideline.

AGREE APPRAISAL INSTRUMENT 

1. SCOPE AND PURPOSE (1-3)
2. STAKEHOLDER INVOLVEMENT (4-7)
3. RIGOUR OF DEVELOPMENT (8-14)
4. CLARITY AND PRESENTATION (15-18)
5. APPLICABILITY (19-21)
- 6. EDITORIAL INDEPENDENCE (22-23)**

Is concerned with the independence of the recommendations and acknowledgement of possible conflict of interest from the guideline development group

1. SCOPE AND PURPOSE (1-3) 

1. The overall objective(s) of the guideline is(are) specifically described.
Comments?

2. The clinical question(s) covered by the guideline is(are) specifically described.
Comments?

3. The patients to whom the guideline is meant to apply are specifically described.
Comments?

2. STAKEHOLDER INVOLVEMENT (4-7) 

4. The guideline development group includes individuals from all the relevant professional groups.
Comments?

5. The patients' views and preferences have been sought.
Comments?

6. The target users of the guideline are clearly defined.
Comments?

7. The guideline has been piloted among target users.
Comments?

3. RIGOUR OF DEVELOPMENT (8-14) 

8. Systematic methods were used to search for evidence
Comments

9. The criteria for selecting the evidence are clearly described
Comments

10. The methods used for formulating the recommendations are clearly described
Comments

11. The health benefits, side effects and risks have been considered in formulating the recommendations
Comments

12. There is an explicit link between the recommendations and the supporting evidence
Comments

13. The guideline has been externally reviewed by experts prior to its publication
Comments

14. A procedure for updating the guideline is provided
Comments

4. CLARITY AND PRESENTATION (15-18)



15. The recommendations are specific and unambiguous

Comments

16. The different options for management of the condition are clearly presented

Comments

17. Key recommendations are easily identifiable

Comments

18. The guideline is supported with tools for application

Comments

5. APPLICABILITY (19-21)



19. The potential organisational barriers in applying the recommendations have been discussed

Comments

20. The potential cost implications of applying the recommendations have been considered

Comments

21. The guideline presents key review criteria for monitoring and/or audit purposes

Comments

6. EDITORIAL INDEPENDENCE (22-23)



22. The guideline is editorially independent from the funding body

Comments

23. Conflicts of interest of guideline development members have been recorded

Comments

Would you recommend these guidelines for use in practice?

- Strongly recommend
- Recommend (with provisos or alterations)
- Would not recommend
- Unsure

Guidelines in Dentistry

- High scores were obtained for the domains: Scope and purpose & Clarity and presentation
- Mediocre scores were obtained for the domains: Stakeholder involvement & Rigour of development
- Low scores were obtained for: Applicability and Editorial independence
- Four of the evaluated guidelines could be strongly recommended for use, three could be recommended and as many as 13 should not be recommended.
- Particularly the criteria lack of independence from sponsoring body and conflict of interest scored low.
- Very few of the guidelines contained explicit links to the scientific evidence.
- The strength of recommendations were seldom presented
